Holen Sie sich die Stockscreener-App
4.13
0.24%
-0.010
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAMP?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$4.14
Offen:
$4.29
24-Stunden-Volumen:
161.12K
Relative Volume:
1.62
Marktkapitalisierung:
$214.45M
Einnahmen:
$3.50M
Nettoeinkommen (Verlust:
$-80.40M
KGV:
-1.6063
EPS:
-2.5711
Netto-Cashflow:
$-29.83M
1W Leistung:
-2.13%
1M Leistung:
-9.43%
6M Leistung:
-33.49%
1J Leistung:
+201.46%
1-Tages-Spanne:
$3.92
$4.4499
1-Wochen-Bereich:
$3.92
$5.25
52-Wochen-Spanne:
$1.305
$7.75
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
Firmenname
Camp 4 Therapeutics Corp
Sektor
Branche
Telefon
617-651-8867
Adresse
ONE KENDALL SQUARE, CAMBRIDGE, CA
Compare CAMP vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
4.13 | 214.45M | 3.50M | -80.40M | -29.83M | -2.5711 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | Rodman & Renshaw | Buy |
| 2025-10-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-09-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-05-27 | Eingeleitet | Wedbush | Outperform |
| 2024-11-05 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-05 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-05 | Eingeleitet | William Blair | Outperform |
| 2022-08-16 | Hochstufung | Craig Hallum | Hold → Buy |
| 2021-12-22 | Herabstufung | Craig Hallum | Buy → Hold |
| 2021-09-24 | Bestätigt | Craig Hallum | Buy |
| 2021-06-25 | Bestätigt | Craig Hallum | Buy |
| 2020-12-18 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-04-17 | Hochstufung | Jefferies | Hold → Buy |
| 2020-03-05 | Bestätigt | Craig Hallum | Buy |
| 2019-12-20 | Bestätigt | Craig Hallum | Buy |
| 2019-12-20 | Herabstufung | First Analysis Sec | Outperform → Neutral |
| 2019-06-28 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2019-05-29 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-01 | Bestätigt | Craig Hallum | Buy |
| 2019-03-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-01-25 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-12-21 | Hochstufung | Craig Hallum | Hold → Buy |
| 2018-12-14 | Bestätigt | B. Riley FBR | Buy |
| 2018-12-11 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
| 2018-12-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-11-27 | Eingeleitet | Goldman | Neutral |
| 2018-10-15 | Eingeleitet | Jefferies | Hold |
| 2018-09-28 | Bestätigt | Craig Hallum | Hold |
| 2018-04-27 | Bestätigt | Craig Hallum | Hold |
| 2018-03-08 | Herabstufung | Craig Hallum | Buy → Hold |
| 2018-02-16 | Hochstufung | First Analysis Sec | Equal-Weight → Overweight |
Alle ansehen
Camp 4 Therapeutics Corp Aktie (CAMP) Neueste Nachrichten
CAMP4 lures 3 new hires with 39,000 stock options - Stock Titan
CAMP4 Therapeutics Corp (CAMP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CAMP4 Therapeutics Corp (CAMP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CAMP4 Therapeutics Corp (CAMP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CAMP4 Therapeutics Corp (CAMP) Institutional Confidence - TradingKey
CAMP4 Therapeutics Corp (CAMP) Valuation: PE, PB & Fair Value Analysis - TradingKey
CAMP4 Therapeutics Corp (CAMP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CAMP4 Therapeutics Corp (CAMP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CAMP4 Therapeutics Corp (CAMP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
This Exxon Mobil Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
JPMorgan upgrades CAMP4 Therapeutics stock rating on CMP-002 potential - Investing.com
CAMP4 Shareholders Approve Equity Plan Changes and Inducement Plan - TipRanks
Camp4 Therapeutics (CAMP) director awarded 28,000 stock options - Stock Titan
Camp4 Therapeutics (CAMP) grants director 28,000 stock options - Stock Titan
Camp4 Therapeutics (CAMP) director granted options on 28,000 shares at $4.34 - Stock Titan
Camp4 Therapeutics director granted 28,000 options | CAMP Insider Trading - Stock Titan
Camp4 Therapeutics (CAMP) director awarded 28,000 stock options at $4.34 strike - Stock Titan
Camp4 Therapeutics director granted 28K options | CAMP Insider Trading - Stock Titan
CAMP4 Therapeutics (NASDAQ: CAMP) updates equity plans and elects Class II directors - Stock Titan
CAMP Initiated Coverage by Chardan Capital -- Rating Set to Buy - GuruFocus
Chardan initiates CAMP4 Therapeutics stock with buy rating - Investing.com UK
Chardan initiates CAMP4 Therapeutics stock with buy rating By Investing.com - Investing.com Australia
CAMP4 Therapeutics Q1 2026 Earnings: EPS Misses Estimates by 49.4% as Pre-Revenue Biotech Faces R&D Cost PressureEPS Estimate Trend - newsline.com
Here's Why We're Not Too Worried About Camp4 Therapeutics' (NASDAQ:CAMP) Cash Burn Situation - Yahoo Finance
CAMP4 Therapeutics Gains 3.12% as Shares Test Key Resistance at $4.51Gap Fill Strategy - newsline.com
CAMP Technical Analysis | Trend, Signals & Chart Patterns | CAMP4 THERAPEUTICS CORP (NASDAQ:CAMP) - ChartMill
CAMP4 Therapeutics (CAMP) Edges Higher Amid Continued VolatilityRisk Reward Setups - The Legal Advocate
CAMP4 Therapeutics Surges 4.5% as Biotech Sentiment Improves — CAMP Tests Key ResistanceMomentum Stock Picks - newsline.com
CAMP Q1 2026 Earnings: Wider-Than-Expected Loss Pressures Sentiment, but Stock Holds SteadyProduct Revenue Analysis - The Legal Advocate
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Camp4 Therapeutics Corp CEO unveils gene expression strategy with regRNA for rare disease therapy - Traders Union
Camp4 studies CMP-002 in SYNGAP1 haploinsufficient mouse model - BioWorld News
Balyasny Asset Management (CAMP) reports 2.63M shares; 4.99% warrant blocker - Stock Titan
CAMP4 Therapeutics Reports Preclinical Success of CMP-002 in Reducing Seizures for SYNGAP1-Related Disorder, Plans Phase 1/2 Trial in 2026 - Minichart
CAMP4 Highlights Preclinical Progress of SYNGAP1 Therapy - TipRanks
CAMP4 reports positive preclinical seizure data for CMP-002 - Investing.com
Camp4 Therapeutics Corp unveils new preclinical data on SYNGAP1 seizure model in Boston - Traders Union
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder - The Manila Times
CAMP4 Therapeutics to Present New Preclinical Data - GlobeNewswire
Camp4 Therapeutics Corp targets capital discipline with new R and D focus - Traders Union
CAMP4 Therapeutics Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Camp4 Therapeutics Corp posts Q1 2026 financial results and reveals corporate developments - Traders Union
CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Rare-disease drug moves toward human trial as CAMP4 projects cash into 2028 - Stock Titan
CAMP4 Therapeutics (NASDAQ: CAMP) details Q1 2026 results and cash runway into 2028 - Stock Titan
Camp4 Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
CAMP4 Therapeutics (CAMP) posts Q1 2026 loss but keeps cash runway into 2028 - Stock Titan
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights - GlobeNewswire
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Finanzdaten der Camp 4 Therapeutics Corp-Aktie (CAMP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):